Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.67 USD | +0.78% | +7.05% | +75.05% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
Financials (USD)
Sales 2024 * | 5.84M | Sales 2025 * | 4.43M | Capitalization | 1.51B |
---|---|---|---|---|---|
Net income 2024 * | -174M | Net income 2025 * | -193M | EV / Sales 2024 * | 149 x |
Net cash position 2024 * | 638M | Net cash position 2025 * | 333M | EV / Sales 2025 * | 265 x |
P/E ratio 2024 * |
-9
x | P/E ratio 2025 * |
-10.5
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.57% |
Latest transcript on Spyre Therapeutics, Inc.
1 day | +0.78% | ||
1 week | +14.08% | ||
Current month | +14.05% | ||
1 month | +1.26% | ||
3 months | +66.98% | ||
6 months | +248.47% | ||
Current year | +75.05% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 34 | 23-06-21 |
Scott Burrows
DFI | Director of Finance/CFO | 47 | 23-08-31 |
Brian Connolly
CTO | Chief Tech/Sci/R&D Officer | - | Nov. 26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tomas Kiselak
BRD | Director/Board Member | 38 | 23-06-21 |
Jeffrey Albers
BRD | Director/Board Member | 52 | Nov. 26 |
Peter Harwin
BRD | Director/Board Member | 38 | 23-06-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 37.8 | +1.12% | 282,967 |
24-05-15 | 37.38 | -4.86% | 299,261 |
24-05-14 | 39.29 | +6.19% | 400,122 |
24-05-13 | 37 | +0.19% | 274,679 |
24-05-10 | 36.93 | +4.94% | 429,293 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.05% | 1.51B | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- SYRE Stock